1. Congenital heart disease cardiac catheterization at Uganda Heart Institute, a 12-year retrospective study of immediate outcomes
- Author
-
Nestor Mbabazi, Twalib Aliku, Judith Namuyonga, Hilda Tumwebaze, Emma Ndagire, Bernard Obongonyinge, Rebecca Esther Khainza, Mary Teddy Akech, Killen Angelline, Aisha Nakato, Cornelius Ssendagire, Lameck Ssemogerere, Michael Oketcho, John Omagino, Peter Lwabi, and Sulaiman Lubega more...
- Subjects
Congenital Heart Disease ,Cardiac Catheterization ,Uganda ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Cardiac catheterization is an invasive diagnostic and treatment tool for congenital heart disease (CHD) with potential complications. Objective To describe the immediate outcomes of patients who underwent cardiac catheterization for CHD at the Uganda Heart Institute (UHI). Methods The study was a retrospective chart review of 857 patients who underwent cardiac catheterization for CHD at UHI from 1st February 2012 to 30th June 2023. Precardiac catheterization clinical data, procedure details, and post-procedure data were recorded. The statistical software SPSS was used for data analysis. Results We studied 857 patients who underwent cardiac catheterization for CHD at UHI. Females comprised 62.8% (n = 528). The age range was 3 days to 64 years, with a mean of 5.1 years (SD 7.4). Advanced heart failure was present in 24(2.8%) of the study participants. The most common procedures were patent ductus arteriosus device closure (n = 500, 58.3%), diagnostic catheterization (n = 194, 22.5%), and balloon pulmonary valvuloplasty (n = 114, 13.0%). PDA device closure had 89.4% optimal results while BPV had 75.9% optimal performance outcome. Adverse events occurred in 52 out of 857 study participants (6.1%). Clinically meaningful adverse events (CMAES) occurred in 3.9%, (n = 33), high severity adverse events in 2.9% (n = 25) and mortality in 1.5% (n = 13). Advanced heart failure at the time of cardiac catheterization, was significantly associated with clinically meaningful adverse events (OR 52 p-value more...
- Published
- 2024
- Full Text
- View/download PDF